Serum protein levels following surgery in breast cancer patients: A protein microarray approach

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2200-2206

  Perez Rivas, Luis G ^a   Jerez, Jose M ^b   Fernandez De Sousa, Cristina E ^a   De Luque, Vanessa ^a   Quero, Cristina ^a   Pajares, Bella ^a   Franco, Leonardo ^b   Sanchez Muñoz, Alfonso ^a   Ribelles, Nuria ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Breast cancer; Dormancy; Reverse phase protein array; Serum protein profile; Surgery

Indexed keywords

ALPHA FETOPROTEIN; BETA1 INTERFERON; BLOOD CLOTTING FACTOR 13A; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS LIGAND; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; MATRILYSIN; PLATELET DERIVED GROWTH FACTOR B; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN A; VASCULOTROPIN B;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; BREAST SURGERY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84869782302     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1667     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Perou CM, Sørlie T, Eisen MB, van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
3. Anderson WF and Matsuno R: Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst 98: 948-951, 2006. (Pubitemid 44288160)
4. Børresen-Dale AL, Sørlie T and Kristensen VN: On the molecular biology of breast cancer. Mol Oncol 4: 171-173, 2010.
5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van De Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001. (Pubitemid 32878711)
6. Baum M, Demicheli R, Hrushesky W and Retsky MW: Does surgery unfavourably perturb the 'natural history' of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer 41: 508-515, 2005. (Pubitemid 40292730)
7. Demicheli R, Retsky MW, Hrushesky WJM, Baum M and Gukas ID: The effects of surgery on tumor growth: a century of investigations. Ann Oncol 19: 1821-1828, 2008.
8. Fehm T, Mueller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E and Becker S: Tumor cell dormancy: implications for the biology and treatment of breast cancer. Acta Pathol Microbiol Immunol Scand 116: 742-753, 2008.
9. Tseng WW, Fadaki N and Leong SP: Metastatic tumor dormancy in cutaneous melanoma: Does surgery induce escape? Cancers 3: 730-746, 2011.
10. Retsky MW, Demicheli R, Hrushesky W, Baum M and Gukas I: Surgery triggers outgrowth of latent distant disease in breast cancer: An inconvenient truth? Cancers 2: 305-337, 2010.
11. Uhr JW and Pantel K: Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 108: 1-5, 2011.
12. Demicheli R, Retsky MW, Hrushesky WJM and Baum M: Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 4: 699-710, 2007. (Pubitemid 350187005)
13. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846, 2007.
14. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG and Redmond HP: Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 4: 760-768, 2003. (Pubitemid 37527212)
15. Spurrier B, Honkanen P, Holway A, Kumamoto K, Terashima M, Takenoshita S, Wakabayashi G, Austin J and Nishizuka S: Protein and lysate array technologies in cancer research. Biotechnol Adv 26: 361-369, 2008.
16. Mueller C, Liotta La and Espina V: Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 4: 1-21, 2010.
17. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, et al: Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4: 346-355, 2005. (Pubitemid 40590555)
18. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB and Kornblau SM: Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512-2521, 2006. (Pubitemid 44650915)
19. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F and Gallagher WM: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 10: 605-617, 2010.
20. Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, Whitcomb DC and Logsdon CD: Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8: 3051-3060, 2008.
21. Holdaway IM, Lethaby AE, Mason BH, Singh V, Harman JE, MacCormick M and Civil ID: Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions. Ann Surg Oncol 8: 25-31, 2001. (Pubitemid 32126822)
22. Smyth GK: Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry R and Huber W (eds). Springer, New York, NY, pp397-420, 2005.
23. Yang YH and Thorne NP: Normalization for two-color cDNA microarray data. Institute of Mathematical Statistics, 2003.
24. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Gen Mol Biol 3: Article3, Feb 12, 2004 (Epub ahead of print).
25. Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Stat Method) 57: 289-300, 1995.
26. Carlsson A, Wingren C, Kristensson M, Rose C, Fernö M, Olsson H, Jernström H, Ek S, Gustavsson E, Ingvar C, et al: Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci USA 108: 14252-14257, 2011.
27. Gurtner GC, Werner S, Barrandon Y and Longaker MT: Wound repair and regeneration. Nature 453: 314-321, 2008. (Pubitemid 351693137)
28. Hamilton JA: Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8: 533-544, 2008.
29. Lin Z-Q, Kondo T, Ishida Y, Takayasu T and Mukaida N: Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 73: 713-721, 2003. (Pubitemid 38040449)
30. Oshika Y, Masuda K, Tokunaga T, Hatanaka H, Kamiya T, Abe Y, Ozeki Y, Kijima H, Yamazaki H, Tamaoki N, et al: Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res 4: 1785-1788, 1998. (Pubitemid 28304743)
31. Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T, et al: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 79: 354-359, 1999. (Pubitemid 29002307)
32. Maclauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P and Kyriakides TR: Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem 57: 301-313, 2009.
33. Kyriakides TR, Tam JW and Bornstein P: Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113: 782-787, 1999.
34. Jameson J and Havran WL: Skin gammadelta T-cell functions in homeostasis and wound healing. Immunol Rev 215: 114-122, 2007. (Pubitemid 46212234)
35. Al-Rawi MAA, Watkins G, Mansel RE and Jiang WG: The effects of interleukin-7 on the lymphangiogenic properties of human endothelial cells. Int J Oncol 27: 721-730, 2005.
36. Cruikshank W and Little F: lnterleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol 28: 467-483, 2008.
37. + mononuclear cells through the expression of interleukin-16. Circulation 113: 118-124, 2006.
38. Al-Rawi MAA, Rmali K, Watkins G, Mansel RE and Jiang WG: Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 40: 494-502, 2004. (Pubitemid 38220764)
39. Germano G, Allavena P and Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374-379, 2008.
40. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Huang T, Chan MWY, Marini FC, Rosol TJ, et al: Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68: 9087-9095, 2008.
41. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
42. Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Borrebaeck CAK, Baldertorp B, Fernö M and Olsson H: Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 44: 472-480, 2008. (Pubitemid 351179627)
43. Gast M-CW, Zapatka M, van Tinteren H, Bontenbal M, Span PN, Tjan-Heijnen VCG, Knol JC, Jimenez CR, Schellens JHM and Beijnen JH: Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. J Cancer Res Clin Oncol 137: 1773-1783, 2011.
44. Pietrowska M, Polanska J, Marczak L, Behrendt K, Nowicka E, Stobiecki M, Polanski A, Tarnawski R and Widlak P: Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J Transl Med 8: 66, 2010.